Cell, gene therapy companies pressured by supply and manufacturing issues -BTIG

Mustang Bio

20/01/2022 14:55

** Biotech companies developing cell and gene therapies are
fighting supply chain shortages resulting in difficulty with
respect to maintaining continuity of production, brokerage BTIG
says, citing industry experts
    ** From reagents and viral vectors used in manufacturing to
pipette tips used for bench work, multiple supplies have been
difficult to obtain where these materials are used in multiple
steps of production of these high-value products, brokerage says
    ** Says these shortages extend to backlogs at contract
manufacturers, with raw materials for cell production being
difficult to obtain as well as long queues to reserve slots for
third-party equipment such as bioreactors
    ** Multiple third-party manufacturing organizations are
involved in COVID-related production, which is prioritized and
thus impacts the queue for other clients - BTIG
    ** Recent regulatory setbacks for companies such as Revance
Therapeutics  RVNC.O , Sesen Bio  SESN.O  and CorMedix  CRMD.O 
due to manufacturing issues highlights the importance of
manufacturing and quality control issues, brokerage says
 urn:newsml:reuters.com:*:nL4N2RB3L5  urn:newsml:reuters.com:*:nL1N2PK1U9  urn:newsml:reuters.com:*:nL3N2KZ42P

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; +91  8061822700;))